The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer

被引：3
|
作者：
Gil, Hyun-Il [1 ]
Um, Sang-Won [1 ]
机构：
[1] Sungkyunkwan Univ, Div Pulm & Crit Care Med, Dept Med, Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
来源：
JOURNAL OF THORACIC DISEASE | 2020年 / 12卷 / 03期
基金：
新加坡国家研究基金会;
关键词：
POPULATION PHARMACOKINETICS; OPEN-LABEL; ERLOTINIB; MULTICENTER; GEFITINIB; AZD9291; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; RESISTANCE;
D O I：
10.21037/jtd.2019.12.80
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：153 / 155
页数：3
相关论文
共 50 条
  • [1] Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
    Lamberti, Giuseppe
    Andrini, Elisa
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1831 - S1834
  • [2] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Joan Rou-En Choo
    Chee-Seng Tan
    Ross A. Soo
    Targeted Oncology, 2018, 13 : 141 - 156
  • [3] Osimertinib in EGFR T790M-Positive Lung Cancer
    Nishino, Mizuki
    Hatabu, Hiroto
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20): : 1992 - 1993
  • [4] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Choo, Joan Rou-En
    Tan, Chee-Seng
    Soo, Ross A.
    TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
  • [5] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
    Lamb, Yvette N.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (04) : 555 - 562
  • [6] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
    Yvette N. Lamb
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 555 - 562
  • [7] Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
    Kim, Hye Sook
    Lim, Kun Young
    Lee, Soo-Hyun
    Kim, Hyae Young
    Lee, Youngjoo
    Han, Ji-Youn
    CANCER MEDICINE, 2023, 12 (11): : 12285 - 12298
  • [8] Osimertinib effective in EGFR T790M-positive lung cancer
    Mayor, Susan
    LANCET ONCOLOGY, 2017, 18 (01): : E9 - E9
  • [9] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Filipits, Martin
    TARGETED ONCOLOGY, 2021, 16 (01) : 77 - 84
  • [10] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
    Anna Buder
    Maximilian J. Hochmair
    Martin Filipits
    Targeted Oncology, 2021, 16 : 77 - 84
12345